Whole genome sequencing and analysis of live biotherapeutic products
European Pharmaceutical Review
DECEMBER 21, 2022
The US Food and Drug Administration (FDA) created live biotherapeutic products (LBP) as a new category in the 2012 guidelines. EMA and FDA have given prime importance to the whole genome sequence characterisation of the strain in the final product dossier.
Let's personalize your content